Skip to content

Total debt at other companies

Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$377.3M+187%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$47.86M-5.8%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$31.57M-33.1%
Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.53B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $137K.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's total debt?
Viking Therapeutics (VKTX) reported total debt of $137K in Q4 2025.
How has Viking Therapeutics's total debt changed year-over-year?
Viking Therapeutics's total debt decreased by 87.8% year-over-year, from $1.12M to $137K.
What is the long-term trend for Viking Therapeutics's total debt?
Over 5 years (2020 to 2025), Viking Therapeutics's total debt has grown at a -17.5% compound annual growth rate (CAGR), from $359K to $137K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.